The licensing of radiogel could bring substantially huge revenues to ADMD. From what I have read in some trade journals recently, it seems that this approach delivers higher efficacy with less toxicity. The company has serious upside here.
You are correct. More efficacy with less toxicity. Radiogel contains microspheres of yttrium 90. The polymer is in liquid form when it's injected and quickly turns into a gel at body temperature and stays in place.
The polymer binds the microspheres in place as the yttrium 90 bombards the cancer with radiation, with little of the radiation reaching nearby healthy tissue. It has applications for cancers of the liver, brain, head and neck, kidney and pancreas, and is showing promise for eye tumors.
The main selling point with RADIOGEL is that it tackles a major problem with radiation cancer treatments: and that is the damage caused to healthy body tissues. radiogel fixes that problem by locking in and localizing the radiation to the tumor or cancer tissues only.